Under fjärde kvartalet levererade Botnia sin första guldtacka till kund.
Sales in line with cons, adj. EBITA -7% vs cons Consensus EBITA estimate revisions slightly negative...
Redeye return with a research update following BioArctic's Q4 report and recent events, including th...
Redeye provides an initial comment on the Q4 2024 report from Cheffelo, which was in line with annou...
External manufacturing and Artscape raise growth to 6% y-o-y DTC grew 100% y-o-y in 2024, more to co...
Sales -5% vs. cons, adj. EBITA -33% vs. cons Enters Norway with Habberstad acquisition Acquisition o...
Redeye provides an update following Truecaller’s Q4 2024 report, which exceeded expectations across ...
Redeye states CoinShares Q4 2024 report exceeded Redeye Research estimates (RRe) across all segments...
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and dire...
Strong Q4 organic growth and double-digit '25 target 10-8% EPS downgrades for '25e-'27e Trading well...
CirChem har publicerat bolagets delårsrapport för det fjärde kvartalet 2024.
Earnings growth to pick up in 2025 EBIT raised by 3% for 2025e 2025e-26e EV/EBIT of 4x with easy com...
Justerat för jämförelsestörande poster kom rapporten in över vår prognos.
Net sales of SEK46m were in line with our estimates, while EBIT exceeded expectations by SEK10m.
Aspo’s Q4 figures weren’t yet great, even if they improved a bit y/y, as ESL particularly had to end...
